PCa Commentary | Volume 169 – September 2022
This Commentary looks at ADT and radiotherapy, as well as evolution of cellular resistance to ADT therapy and potential treatment.
Read MoreSelect Page
Posted by Edward Weber, MD | Sep 2022
This Commentary looks at ADT and radiotherapy, as well as evolution of cellular resistance to ADT therapy and potential treatment.
Read MorePosted by Paul Boutros, PhD, MBA | Sep 2022
Paul C. Boutros, PhD, MBA, examines germline genetics and urine characteristics of prostate cancer and how these relate to aggression.Paul C. Boutros, PhD, MBA, examines germline genetics and urine characteristics of prostate cancer and how these relate to aggression.
Read MorePosted by Peter J. Rossi, MD | Aug 2022
Peter J. Rossi, MD, a board-certified radiation oncologist affiliated with Calaway Young Cancer Center at Valley View Hospital in Glenwood Springs, Colorado discusses innovations and advances in low-dose-rate (LDR) and high-dose-rate (HDR) prostate brachytherapy as well as American Brachytherapy Society (ABS) initiatives and training opportunities. Dr. Rossi explains that innovations have resulted in brachytherapy treatment that is evidence-based, innovative, efficient, cost effective, flexible, yields highly personalized treatment, and is of high value to multidisciplinary teams and to patients.
Read MorePosted by Ilya Gipp, MD, PhD | Aug 2022
In this presentation, given during the 2021 Virtual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer and supported by Philips, Ilya Gipp, MD, PhD, a medical officer and oncology solutions subject matter expert with Philips in Atlanta, Georgia, discusses solutions for integrating data to personalize prostate cancer care. He first describes positive trends and challenges in prostate cancer care, noting that data silos across service lines and service providers remain a key barrier to effective and efficient treatment. Dr. Gipp describes the prostate cancer service line as beginning with early detection, progressing to diagnosis and staging, treatment selection, therapy planning and deployment, and assessment and follow-up. He then focuses on the actionability and insightfulness of information, and how to synthesize data throughout the cancer care pathway using magnetic resonance imaging (MRI). Dr. Gipp remarks that while MRI is often used in diagnosis, to benefit from the data, MRI must be the modality used at all points from screening to post-therapy assessment. For example, MRI can generate images similar to CT scans for radiation dose planning as well as guiding dose painting to offer localized, non-uniform radiation dose distribution. He summarizes by comparing the traditional approach to cancer care with a state-of-the-art model that employs biomarker imaging, image-guided multi-modality navigated fusion biopsies, digital pathology, and focal therapies.
Read MorePosted by Wolfgang Weber, MD | Aug 2022
In this 6-minute presentation, presented during the 2021 Virtual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer and supported by Blue Earth Diagnostics, Wolfgang Weber, MD, Professor and Chair of the Department of Nuclear Medicine at the Technical University of Munich in Germany (TUM), discusses 18F-rhPSMA7(.3) as a promising tracer for imaging prostate cancer for primary staging and in the case of biochemical recurrence, explaining that limited renal excretion facilitates evaluation of the prostate and the prostate bed before surgery. Dr. Weber explains that prospective registration trials have completed accrual, and the use of radiohybrid prostate-specific membrane antigen ligands (rhPSMAs) for therapy of prostate cancer is being evaluated preclinically.
Read More